The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Abstract
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationCrizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationOsimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Self-citationStandards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Self-citationTorre, L. A., Siegel, R. L., & Jemal, A. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-24223-1_1 · Cited by 1,903
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,798
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Self-citationEberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461
Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,354
Self-citationPirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Vynnychenko, I., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,351
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Camidge, D. R., Bang, Y.-J., Kwak, E. L., Iafrate, A. J., Varella-Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S.-H. I., Kim, D.-W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,268
Self-citationGainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Wu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,189
Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183
The protein tyrosine kinase family of the human genome
Robinson, D. R., Wu, Y.-M., & Lin, S.-F. (2000) · Oncogene · doi:10.1038/sj.onc.1203957 · Cited by 1,167
Garon, E. B., Hellmann, M. D., Rizvi, N. A., Carcereny, E., Leighl, N. B., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00934 · Cited by 1,163
Self-citationSoria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D.-W., Mok, T., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,099
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Self-citationYang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002
Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S. V., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002787 · Cited by 1,000
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980
Self-citationMerker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8671 · Cited by 959
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0013 · Cited by 948
Self-citationRobson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Plon, S. E., Eccles, D. M., Easton, D., Foulkes, W. D., Genuardi, M., Greenblatt, M. S., Hogervorst, F. B. L., Hoogerbrugge, N., Spurdle, A. B., Tavtigian, S. V., et al. (2008) · Human Mutation · doi:10.1002/humu.20880 · Cited by 912
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 911
Planchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazieres, J., Viteri, S., Senellart, H., Van Meerbeeck, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004407 · Cited by 870
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7162 · Cited by 850
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005653 · Cited by 828
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796
Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30649-1 · Cited by 791
Self-citationGuidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
Jennings, L. J., Arcila, M. E., Corless, C., Kamel-Reid, S., Lubin, I. M., Pfeifer, J., Temple-Smolkin, R. L., Voelkerding, K. V., & Nikiforova, M. N. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.01.011 · Cited by 743
Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Management of non-small-cell lung cancer: recent developments
Reck, M., Heigener, D. F., Mok, T., Soria, J.-C., & Rabe, K. F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61502-0 · Cited by 714
Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., Heng, J. C., Dahlberg, S. E., Jänne, P. A., Verma, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4600 · Cited by 693
Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H. I., Ahn, J. S., Shaw, A. T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.478 · Cited by 686
Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668
Borghaei, H., Gettinger, S., Vokes, E. E., Chow, L. Q. M., Burgio, M. A., de Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O. A., Chiari, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01605 · Cited by 656
Self-citationPark, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00662 · Cited by 655
Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citationFinlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636
Saito, H., Fukuhara, T., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., Yoshimori, K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30035-x · Cited by 615
Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., Chiu, C.-H., Park, K., Novello, S., Nadal, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30634-5 · Cited by 603
Costa, D. B., Shaw, A. T., Ou, S.-H. I., Solomon, B. J., Riely, G. J., Ahn, M.-J., Zhou, C., Shreeve, S. M., Selaru, P., Polli, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0539 · Cited by 599
Self-citationKosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 589
Kim, D.-W., Tiseo, M., Ahn, M.-J., Reckamp, K. L., Hansen, K. H., Kim, S.-W., Huber, R. M., West, H. L., Groen, H. J. M., Hochmair, M. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5904 · Cited by 581
Self-citationLisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.035 · Cited by 580
Ou, S.-H. I., Ahn, J. S., De Petris, L., Govindan, R., Yang, J. C.-H., Hughes, B., Lena, H., Moro-Sibilot, D., Bearz, A., Ramirez, S. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 580
Shaw, A. T., Riely, G. J., Bang, Y.-J., Kim, D.-W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz131 · Cited by 576
Self-citationPaik, P. K., Drilon, A., Fan, P.-D., Yu, H., Rekhtman, N., Ginsberg, M. S., Borsu, L., Schultz, N., Berger, M. F., Rudin, C. M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1467 · Cited by 575
Sacher, A. G., Paweletz, C., Dahlberg, S. E., Alden, R. S., O’Connell, A., Feeney, N., Mach, S. L., Jänne, P. A., & Oxnard, G. R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0173 · Cited by 571
Shaw, A. T., Kim, T. M., Crinò, L., Gridelli, C., Kiura, K., Liu, G., Novello, S., Bearz, A., Gautschi, O., Mok, T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30339-x · Cited by 567
Li, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 556
Self-citationOsimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Ramalingam, S. S., Yang, J. C.-H., Lee, C. K., Kurata, T., Kim, D.-W., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7576 · Cited by 547
Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., de Braud, F., Rolfo, C., Ahn, M.-J., Wolf, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30690-4 · Cited by 528
Self-citationPaz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J. C.-H., Mok, T., Lee, K. H., Lu, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw611 · Cited by 524
Li, T., Kung, H.-J., Mack, P. C., & Gandara, D. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3753 · Cited by 518
Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7658 · Cited by 505
Camidge, D. R., Dziadziuszko, R., Peters, S., Mok, T., Noe, J., Nowicka, M., Gadgeel, S. M., Cheema, P., Pavlakis, N., de Marinis, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.007 · Cited by 490
Drilon, A., Rekhtman, N., Arcila, M., Wang, L., Ni, A., Albano, M., Van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30562-9 · Cited by 484
Self-citationResponse to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Drilon, A., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P., Ross, J., Miller, V., Ginsberg, M., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 464
Faivre-Finn, C., Vicente, D., Kurata, T., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Spigel, D. R., Garassino, M. C., Reck, M., Senan, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.015 · Cited by 459
Hanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 456
Self-citationPlanchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.-J., Smit, E. F., Groen, H. J. M., Kelly, R. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00077-2 · Cited by 453
Self-citationGainor, J. F., Curigliano, G., Kim, D.-W., Lee, D. H., Besse, B., Baik, C. S., Doebele, R. C., Cassier, P. A., Lopes, G., Tan, D. S. W., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00247-3 · Cited by 440
Mok, T. S., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Lee, M., Linke, R., Rosell, R., Corral, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.7994 · Cited by 439
Soria, J.-C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Isla, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00006-6 · Cited by 433
Ou, S.-H. I., Kwak, E. L., Siwak-Tapp, C., Dy, J., Bergethon, K., Clark, J. W., Camidge, D. R., Solomon, B. J., Maki, R. G., Bang, Y.-J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821528d3 · Cited by 432
Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430
Self-citationChaft, J. E., Oxnard, G. R., Sima, C. S., Kris, M. G., Miller, V. A., & Riely, G. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1468 · Cited by 418
Self-citationDouillard, J.-Y., Ostoros, G., Cobo, M., Ciuleanu, T., McCormack, R., Webster, A., & Milenkova, T. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.721 · Cited by 412
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., Kris, M. G., Riely, G. J., Yu, H. A., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz077 · Cited by 406
Self-citationAntitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Drilon, A., Clark, J. W., Weiss, J., Ou, S.-H. I., Camidge, D. R., Solomon, B. J., Otterson, G. A., Villaruz, L. C., Riely, G. J., Heist, R. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0716-8 · Cited by 395
Self-citationCollege of American Pathologists' Laboratory Standards for Next-Generation Sequencing Clinical Tests
Aziz, N., Zhao, Q., Bry, L., Driscoll, D. K., Funke, B., Gibson, J. S., Grody, W. W., Hegde, M. R., Hoeltge, G. A., Leonard, D. G. B., et al. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0250-cp · Cited by 387
Shaw, A. T., Solomon, B. J., Besse, B., Bauer, T. M., Lin, C.-C., Soo, R. A., Riely, G. J., Ou, S.-H. I., Clancy, J. S., Li, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02236 · Cited by 383
Self-citationJackman, D. M., Miller, V. A., Cioffredi, L.-A., Yeap, B. Y., Jänne, P. A., Riely, G. J., Ruiz, M. G., Giaccone, G., Sequist, L. V., & Johnson, B. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0888 · Cited by 379
Self-citationImplementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr489 · Cited by 370
Self-citationMazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A.-M. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 369
Janjigian, Y. Y., Smit, E. F., Groen, H. J. M., Horn, L., Gettinger, S., Camidge, D. R., Riely, G. J., Wang, B., Fu, Y., Chand, V. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0326 · Cited by 362
Self-citationUpdate on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
Riely, G. J., Politi, K. A., Miller, V. A., & Pao, W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0658 · Cited by 360
Self-citationGautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.9352 · Cited by 360
Self-citationCho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00931 · Cited by 358
Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
Lin, J. J., Cardarella, S., Lydon, C. A., Dahlberg, S. E., Jackman, D. M., Jänne, P. A., & Johnson, B. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.103 · Cited by 356
Self-citationTsurutani, J., Iwata, H., Krop, I., Jänne, P. A., Doi, T., Takahashi, S., Park, H., Redfern, C., Tamura, K., Wise-Draper, T. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1014 · Cited by 354
Antonia, S. J., Borghaei, H., Ramalingam, S. S., Horn, L., De Castro Carpeño, J., Pluzanski, A., Burgio, M. A., Garassino, M., Chow, L. Q. M., Gettinger, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30407-3 · Cited by 351
Self-citationCamidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C. H., Han, J.-Y., Hochmair, M. J., Lee, K. H., Delmonte, A., García Campelo, M. R., Kim, D.-W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00505 · Cited by 351
Self-citationCrinò, L., Ahn, M.-J., De Marinis, F., Groen, H. J. M., Wakelee, H., Hida, T., Mok, T., Spigel, D., Felip, E., Nishio, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5936 · Cited by 350
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 346
Afatinib: First Global Approval
Dungo, R. T., & Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0111-6 · Cited by 329
Johung, K. L., Yeh, N., Desai, N. B., Williams, T. M., Lautenschlaeger, T., Arvold, N. D., Ning, M. S., Attia, A., Lovly, C. M., Goldberg, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0138 · Cited by 328
Self-citationWu, Y.-L., Yang, J. C.-H., Kim, D.-W., Lu, S., Zhou, J., Seto, T., Yang, J.-J., Yamamoto, N., Ahn, M.-J., Takahashi, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5587 · Cited by 326
Tsao, M.-S., Aviel-Ronen, S., Ding, K., Lau, D., Liu, N., Sakurada, A., Whitehead, M., Zhu, C.-Q., Livingston, R., Johnson, D. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6953 · Cited by 325
Oshima, Y., Tanimoto, T., Yuji, K., & Tojo, A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4526 · Cited by 313
Biosimilars: the science of extrapolation
Weise, M., Kurki, P., Wolff-Holz, E., Bielsky, M.-C., & Schneider, C. K. (2014) · Blood · doi:10.1182/blood-2014-06-583617 · Cited by 307
Lim, S. M., Kim, H. R., Lee, J.-S., Lee, K. H., Lee, Y.-G., Min, Y. J., Cho, E. K., Lee, S. S., Kim, B.-S., Choi, M. Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3701 · Cited by 301
Hanna, N. H., Robinson, A. G., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03570 · Cited by 300
Self-citationKerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T., Novello, S., O'Byrne, K., Stahel, R., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 298
Miller, V. A., Riely, G. J., Zakowski, M. F., Li, A. R., Patel, J. D., Heelan, R. T., Kris, M. G., Sandler, A. B., Carbone, D. P., Tsao, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0062 · Cited by 297
Self-citationZhou, C., Ramalingam, S. S., Kim, T. M., Kim, S.-W., Yang, J. C.-H., Riely, G. J., Mekhail, T., Nguyen, D., Garcia Campelo, M. R., Felip, E., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4761 · Cited by 291
Self-citationRiely, G. J., Kris, M. G., Zhao, B., Akhurst, T., Milton, D. T., Moore, E., Tyson, L., Pao, W., Rizvi, N. A., Schwartz, L. H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0560 · Cited by 287
Self-citationKazandjian, D., Blumenthal, G. M., Chen, H.-Y., He, K., Patel, M., Justice, R., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0241 · Cited by 286
Drilon, A., Wang, L., Arcila, M. E., Balasubramanian, S., Greenbowe, J. R., Ross, J. S., Stephens, P., Lipson, D., Miller, V. A., Kris, M. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2683 · Cited by 274
Planchard, D., Besse, B., Groen, H. J. M., Hashemi, S. M. S., Mazieres, J., Kim, T. M., Quoix, E., Souquet, P.-J., Barlesi, F., Baik, C., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.011 · Cited by 272
De Grève, J., Teugels, E., Geers, C., Decoster, L., Galdermans, D., De Mey, J., Everaert, H., Umelo, I., Veld, P. I., & Schallier, D. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.01.008 · Cited by 271
Camidge, D. R., Ou, S.-H. I., Shapiro, G., Otterson, G. A., Villaruz, L. C., Villalona-Calero, M. A., Iafrate, A. J., Varella-Garcia, M., Dacic, S., Cardarella, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8001 · Cited by 256
Self-citationBrahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., Dubinett, S. M., Ferris, A., Gandhi, L., Garon, E. B., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0382-2 · Cited by 253
Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., Reck, M., Smit, E. F., Syrigos, K., Stahel, R., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu123 · Cited by 244
Lee, S.-H., Lee, J.-K., Ahn, M.-J., Kim, D.-W., Sun, J.-M., Keam, B., Kim, T. M., Heo, D. S., Ahn, J. S., Choi, Y.-L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw559 · Cited by 244
Jänne, P. A., Wang, X., Socinski, M. A., Crawford, J., Stinchcombe, T. E., Gu, L., Capelletti, M., Edelman, M. J., Villalona-Calero, M. A., Kratzke, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1315 · Cited by 242
Kazandjian, D., Blumenthal, G. M., Yuan, W., He, K., Keegan, P., & Pazdur, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2266 · Cited by 236
Gridelli, C., Ciardiello, F., Gallo, C., Feld, R., Butts, C., Gebbia, V., Maione, P., Morgillo, F., Genestreti, G., Favaretto, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2056 · Cited by 235
KRAS Mutation: Should We Test for It, and Does It Matter?
Roberts, P. J., & Stinchcombe, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0454 · Cited by 228
Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Costa, D. B., Tsao, A. S., Patel, J. D., Gadgeel, S. M., Bazhenova, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1598 · Cited by 222
Self-citationRecent Clinical Advances in Lung Cancer Management
Johnson, D. H., Schiller, J. H., & Bunn, P. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1228 · Cited by 221
Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer
Ferrara, R., Auger, N., Auclin, E., & Besse, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.021 · Cited by 218
Odogwu, L., Mathieu, L., Blumenthal, G., Larkins, E., Goldberg, K. B., Griffin, N., Bijwaard, K., Lee, E. Y., Philip, R., Jiang, X., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0642 · Cited by 218
HER2 Mutation and Response to Trastuzumab Therapy in Non–Small-Cell Lung Cancer
Cappuzzo, F., Bemis, L., & Varella-Garcia, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmc060020 · Cited by 216
Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211
Self-citationEpidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
Giaccone, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.409 · Cited by 203
RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
Tsuta, K., Kohno, T., Yoshida, A., Shimada, Y., Asamura, H., Furuta, K., & Kushima, R. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.36 · Cited by 202
Relationship Between K-ras Oncogene Activation and Smoking in Adenocarcinoma of the Human Lung
Slebos, R. J. C., Hruban, R. H., Dalesio, O., Mooi, W. J., Offerhaus, G. J. A., & Rodenhuis, S. (1991) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/83.14.1024 · Cited by 202
Symptom Management in Patients With Lung Cancer
Simoff, M. J., Lally, B., Slade, M. G., Goldberg, W. G., Lee, P., Michaud, G. C., Wahidi, M. M., & Chawla, M. (2013) · Chest · doi:10.1378/chest.12-2366 · Cited by 199
Treatment of Stage IV Non-small Cell Lung Cancer
Socinski, M. A., Evans, T., Gettinger, S., Hensing, T. A., VanDam Sequist, L., Ireland, B., & Stinchcombe, T. E. (2013) · Chest · doi:10.1378/chest.12-2361 · Cited by 189
Self-citationTargeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Gautschi, O., Milia, J., Cabarrou, B., Bluthgen, M.-V., Besse, B., Smit, E. F., Wolf, J., Peters, S., Früh, M., Koeberle, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000625 · Cited by 186
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
Tu, H.-Y., Ke, E.-E., Yang, J.-J., Sun, Y.-L., Yan, H.-H., Zheng, M.-Y., Bai, X.-Y., Wang, Z., Su, J., Chen, Z.-H., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.005 · Cited by 182
Leighl, N. B., Hellmann, M. D., Hui, R., Carcereny, E., Felip, E., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30500-9 · Cited by 174
Self-citationCrinò, L., Kim, D., Riely, G. J., Janne, P. A., Blackhall, F. H., Camidge, D. R., Hirsh, V., Mok, T., Solomon, B. J., Park, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7514 · Cited by 171
Self-citationBurotto, M., Manasanch, E. E., Wilkerson, J., & Fojo, T. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0154 · Cited by 168
Crizotinib in Patients With MET-Amplified NSCLC
Camidge, D. R., Otterson, G. A., Clark, J. W., Ignatius Ou, S.-H., Weiss, J., Ades, S., Shapiro, G. I., Socinski, M. A., Murphy, D. A., Conte, U., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.010 · Cited by 166
Self-citationUncommon EGFR mutations in advanced non-small cell lung cancer
O'Kane, G. M., Bradbury, P. A., Feld, R. D., Leighl, N. B., Liu, G., Pisters, K.-M., Kamel‐Reid, S., Tsao, M., & Shepherd, F. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.016 · Cited by 165
Sequist, L. V., Joshi, V. A., Jänne, P. A., Muzikansky, A., Fidias, P., Meyerson, M., Haber, D. A., Kucherlapati, R., Johnson, B. E., & Lynch, T. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-90 · Cited by 162
Urata, Y., Katakami, N., Morita, S., Kaji, R., Yoshioka, H., Seto, T., Satouchi, M., Iwamoto, Y., Kanehara, M., Fujimoto, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4154 · Cited by 159
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig, S. J., & Shapiro, G. I. (2010) · PubMed · Cited by 155
Khozin, S., Blumenthal, G. M., Jiang, X., He, K., Boyd, K. K., Murgo, A. J., Justice, R. L., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0089 · Cited by 150
Kawashima, Y., Fukuhara, T., Saito, H., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00166-1 · Cited by 150
Onitsuka, T., Uramoto, H., Nose, N., Takenoyama, M., Hanagiri, T., Sugio, K., & Yasumoto, K. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.022 · Cited by 147
Pacheco, J. M., Gao, D., Smith, D. E., Purcell, T., Hancock, M. J., Bunn, P. A., Robin, T. P., Liu, A. J., Karam, S. D., Gaspar, L. E., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.014 · Cited by 147
Self-citationNext-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges
Luthra, R., Chen, H., Roy‐Chowdhuri, S., & Singh, R. R. (2015) · Cancers · doi:10.3390/cancers7040874 · Cited by 146
Larkins, E. A., Blumenthal, G. M., Chen, H., He, K., Agarwal, R., Gieser, G., Stephens, O., Zahalka, E. A., Barnett-Ringgold, K., Helms, W. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1293 · Cited by 135
Michels, S. Y. F., Massutí, B., Schildhaus, H., Franklin, J. G., Sebastian, M., Felip, E., Grohé, C., Rodríguez‐Abreu, D., Abdulla, D. S. Y., Bischoff, H. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.020 · Cited by 135
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
Agulnik, M., Nelson, Ziehr, & Johnson, J. R. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s23165 · Cited by 134
Targeted therapy for non-small-cell lung cancer: past, present and future
Forde, P. M., & Ettinger, D. S. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.47 · Cited by 134
Self-citationCamidge, D. R., Bang, Y., Kwak, E. L., Shaw, A. T., Iafrate, A. J., Maki, R. G., Solomon, B., Ou, S.-H. I., Salgia, R., Wilner, K. D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2501 · Cited by 134
Liu, D., Offin, M. D., Harnicar, S. J., Li, B. T., & Drilon, A. E. D. C. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s147381 · Cited by 131
Kim, H. R., Lim, S., Kim, H. J., Hwang, S., Park, J. K., Shin, E., Bae, M., Ou, S.-H. I., Wang, J., Jewell, S. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt220 · Cited by 128
Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer
Sandler, A. B., Johnson, D. H., & Herbst, R. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040023 · Cited by 125
Mok, T. S. K., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Chawla, A., Rosell, R., Corral, J., Migliorino, M. R., et al. (2020) · Drugs · doi:10.1007/s40265-020-01441-6 · Cited by 123
Smit, E. F., Nakagawa, K., Nagasaka, M., Felip, E., Goto, Y., Li, B. T., Pacheco, J. M., Murakami, H., Barlési, F., Saltos, A. N., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9504 · Cited by 117
Self-citationThe Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer
Cardarella, S., Ortiz, T. M., Joshi, V. A., Butaney, M., Jackman, D. M., Kwiatkowski, D. J., Yeap, B. Y., Janne, P. A., Lindeman, N. I., & Johnson, B. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745bcb · Cited by 116
Kawashima, Y., Fukuhara, T., Saito, H., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., et al. (2022) · Institutional Repositories DataBase (IRDB) · Cited by 106
Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
Lin, J. J., Kennedy, E., Sequist, L. V. D., Brastianos, P. K., Goodwin, K. E., Stevens, S. E., Wanat, A. C., Stober, L. L., Digumarthy, S. R., Engelman, J. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.126 · Cited by 104
Self-citationYang, J. C., Cho, B. C., Kim, D., Kim, S., Lee, J.-S., Su, W., John, T., Kao, S. C.-H., Natale, R. B., Goldman, J. W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2020 · Cited by 95
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
Riely, G. J., & Yu, H. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3154 · Cited by 93
Self-citationVasconcelos, P. E. N. S., Gergis, C., Viray, H., Varkaris, A. S., Fujii, M., Rangachari, D., VanderLaan, P. A., Kobayashi, I. S., Kobayashi, S. S., & Costa, D. B. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100051 · Cited by 93
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients
Michels, S., Scheel, A. H., Scheffler, M., Schultheis, A. M., Gautschi, O., Aebersold, F., Diebold, J., Pall, G., Rothschild, S., Bubendorf, L., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.016 · Cited by 91
Kreuter, M., Vansteenkiste, J., Fischer, J. R., Eberhardt, W., Zabeck, H., Kollmeier, J., Serke, M. H., Frickhofen, N., Reck, M., Engel-Riedel, W., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds578 · Cited by 89
Frampton, J. E. (2013) · Drugs · doi:10.1007/s40265-013-0142-z · Cited by 81
Langer, C. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8782 · Cited by 79
Kazandjian, D. G., Blumenthal, G. M., Luo, L., He, K., Fran, I., Lemery, S. J., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0101 · Cited by 76
Brosnan, E. M., Weickhardt, A. J., Lu, X. J. D., Maxon, D. A., Barón, A. E., Chonchol, M., & Camidge, D. R. (2013) · Cancer · doi:10.1002/cncr.28478 · Cited by 72
Managing Treatment–Related Adverse Events Associated with Alk Inhibitors
Rothenstein, J. M., & Letarte, N. (2014) · Current Oncology · doi:10.3747/co.21.1740 · Cited by 70
Reinmuth, N., Bryl, M., Bondarenko, I., Syrigos, K., Vladimirov, V. I., Zereu, M., Bair, A. H., Hilton, F., Liau, K., & Kasahara, K. (2019) · BioDrugs · doi:10.1007/s40259-019-00363-4 · Cited by 64
Pop, O., Pirvu, A., Toffart, A., & Moro‐Sibilot, D. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318257fc1d · Cited by 63
Ten Years of Progress in Non–Small Cell Lung Cancer
Ettinger, D. S. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0029 · Cited by 63
Self-citationLam, V. K. L., Tran, H. T., Banks, K. C., Lanman, R. B., Rinsurongkawong, W., Peled, N., Lewis, J., Lee, J. J., Roth, J. A., Roarty, E. B., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.020 · Cited by 63
Sands, J. M., Nguyen, T. T., Shivdasani, P., Sacher, A. G., Cheng, M. L., Alden, R. S., Janne, P. A., Kuo, F. C., Oxnard, G. R., & Sholl, L. M. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.005 · Cited by 61
Sabari, J. K., Santini, F. C., Schram, A. M., Bergagnini, I., Chen, R., Mrad, C., Lai, W. V., Arbour, K. C., & Drilon, A. E. D. C. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s109295 · Cited by 60
The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
Zhao, D., Chen, X., Qin, N., Su, D., Zhou, L., Zhang, Q., Li, X., Zhang, X., Jin, M., & Wang, J. (2017) · Scientific Reports · doi:10.1038/srep40374 · Cited by 59
Haspinger, E. R., Agustoni, F., Torri, V., Gelsomino, F., Platania, M., Zilembo, N., Gallucci, R., Garassino, M. C., & Cinquini, M. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.11.005 · Cited by 57
Dugay, F., Llamas‐Gutierrez, F., Gournay, M., Médane, S., Mazet, F., Chiforeanu, D. C., Becker, E., Lamy, R., Léna, H., Rioux-Leclercq, N. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18408 · Cited by 51
Cited by
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302983 · Cited by 1,180
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177
Self-citationLi, T., Kung, H.-J., Mack, P. C., & Gandara, D. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3753 · Cited by 518
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J.-S., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., Liu, B., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403614 · Cited by 458
Passaro, A., Wang, J., Wang, Y., Lee, S.-H., Melosky, B., Shih, J.-Y., Wang, J., Azuma, K., Juan-Vidal, O., Cobo, M., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.117 · Cited by 440
Metadata
- Authors
- Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., DeCamp, M., Dilling, T. J., Dowell, J., Gettinger, S., Grotz, T. E., Gubens, M. A., Hegde, A., Lackner, R. P., Lanuti, M., Lin, J., Loo, B. W., Lovly, C. M., Maldonado, F., Massarelli, E., Morgensztern, D., Ng, T., Otterson, G. A., Pacheco, J. M., Patel, S. P., Riely, G. J., Riess, J., Schild, S. E., Shapiro, T. A., Singh, A. P., Stevenson, J., Tam, A., Tanvetyanon, T., Yanagawa, J., Yang, S. C., Yau, E., Gregory, K., & Hughes, M.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2022-05
- Volume
- 20
- Issue
- 5
- Pages
- 497-530
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4280533169
- Cited by
- 1,392
- References
- 217
- FWCI
- 177.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.